Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia

Leukemia

Volumn 18, Issue 3, 2004, Pages 466-475

  Shih, L Y ^a,b   Huang, C F ^a   Wang, P N ^a   Wu, J H ^a   Lin, T L ^a   Dunn, P ^a,b   Kuo, M C ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

AML transformation; FLT3 ITD; FLT3 TKD; Myelodyplastic syndrome; N ras mutation

Indexed keywords

CYTARABINE; DAUNORUBICIN; FLT3 LIGAND; GENOMIC DNA; HYDROXYUREA; ONCOPROTEIN; PROTEIN TYROSINE KINASE; TIOGUANINE; CD135 ANTIGEN; CELL SURFACE RECEPTOR; FLT3 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE ACTIVATION; GENE DUPLICATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; ONCOGENE N RAS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; SAMPLING; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; ACUTE DISEASE; CELL TRANSFORMATION; GENETICS; MIDDLE AGED; MUTATION; MYELOID LEUKEMIA; ONCOGENE RAS; PATHOLOGY;

ACUTE DISEASE; BONE MARROW; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENES, RAS; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CELL SURFACE;

EID: 1542503817     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403274     Document Type: Article

References (46)

1. Mufti GJ, Galton DA. Myelodysplastic syndromes: Natural history and features of prognostic importance. Clin Haematol 1986; 15: 953-971.
2. Raskind WH, Steinmann L, Najfeld V. Clonal development of myeloproliferative disorders: Clues to hematopoietic differentiation and multistep pathogenesis of cancer. Leukemia 1998; 12: 108-116.
3. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 1995; 9: 370-381.
4. Kaneko H, Misawa S, Horiike S, Nakai H, Kashima K. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 1995; 85: 2189-2193.
5. INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985-2990.
6. Beaupre DM, Kurzrock R. RAS and leukemia: From basic mechanisms to gene-directed therapy. J Clin Oncol 1999; 17: 1071-1079.
7. Byrne JL, Marshall CJ. The molecular pathophysiology of myeloid leukaemias: Ras revisited. Br J Haematol 1998; 100: 256-264.
8. Yunis JJ, Boot AJ, Mayer MG, Bos JL. Mechanisms of ras mutation in myelodysplastic syndrome. Oncogene 1989; 4: 609-614.
9. Bar-Eli M, Ahuja H, Gonzalez-Cadavid N, Foti A, Cline MJ. Analysis of N-RAS exon-1 mutations in myelodysplastic syndromes by polymerase chain reaction and direct sequencing. Blood 1989; 73: 281-283.
10. Nakagawa T, Saitoh S, Imoto S, Itoh M, Tsutsumi M, Hikiji K et al. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992; 49: 114-122.
11. Paquette RL, Landaw EM, Pierre RV, Kahan J, Lubbert M, Lazcano O et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82: 590-599.
12. Tien HF, Wang CH, Chuang SM, Chow JM, Lee FY, Liu MC et al. Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome. A study on 68 Chinese patients in Taiwan. Cancer Genet Cytogenet 1994; 74: 40-49.
13. Horiike S, Misawa S, Nakai H, Kaneko H, Yokota S, Taniwaki M et al. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 1994; 8: 1331-1336.
14. Santon A, Arranz E, Robledo M, Prieto E, Benitez J. N-Ras mutations: Incidence and clinical relevance in myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 1995; 50: 315-316.
15. Mitani K, Hangaishi A, Imamura N, Miyagawa K, Ogawa S, Kanda Y et al. No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes. Leukemia 1997; 11: 863-865.
16. Constantinidou M, Chalevelakis G, Economopoulos T, Koffa M, Liloglou T, Anastassiou C et al. Codon 12 ras mutations in patients with myelodysplastic syndrome: Incidence and prognostic value. Ann Hematol 1997; 74: 11-14.
17. Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year follow-up. Leukemia 1998; 12: 887-892.
18. de Souza Fernandez T, Menezes de Souza J, Macedo Silva ML, Tabak D, Abdelhay E. Correlation of N-ras point mutations with specific chromosomal abnormalities in primary myelodysplastic syndrome. Leukemia Res 1998; 22: 125-134.
19. Plata E, Viniou N, Abazis D, Konstantopoulos K, Troungos C, Vaiopoulos G et al. Cytogenetic analysis and RAS mutations in primary myelodysplastic syndromes. Cancer Genet Cytogenet 1999; 111: 124-129.
20. Rosnet O, Stephenson D, Mattei MG, Marchetto S, Shibuya M, Chapman VM et al. Close physical linkage of the FLT1 and FLT3 genes on chromosome 13 in man and chromosome 5 in mouse. Oncogene 1993; 8: 173-179.
21. Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, Toiron Y et al. Human FLT3/FLK2 gene: CDNA cloning and expression in hematopoietic cells. Blood 1993; 82: 1110-1119.
22. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
23. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080.
24. Rombouts WJC, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000; 14: 675-683.
25. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
26. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res 2001; 61: 7233-7239.
27. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
28. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-2439.
29. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia, Br J Haematol 2001; 113: 983-988.
30. Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 1997; 11: 1442-1446.
31. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
32. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H. et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333-1337.
33. Fenski R, Flesch K, Serve S, Mizuki M, Oelmann E, Kratz-Albers K et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol 2000; 108: 322-330.
34. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000; 96: 3907-3914.
35. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H et al. Tandem-duplicated NO constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000; 19: 624-631.
36. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000; 14: 1766-1776.
37. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
38. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
39. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991; 78: 325-329.
40. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
41. Fey MF, Pilkington SP, Summers C, Wainscoat JS. Molecular diagnosis of haematological disorders using DNA from stored bone marrow slides. Br J Haematol 1987; 67: 489-492.
42. Shih LY, Huang CF, Wu JH, Lin TL, Duhn P, Wang PN et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: A comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002; 100: 2387-2392.
43. Liang DC, Shih LY, Hung IJ, Yang CP, Chen SH, Jaing TH et al. FLT3-TKD mutation in childhood acute myeloid leukemia. Leukemia 2003; 17: 883-886.
44. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2003; 100: 2393-2398.
45. van Kamp H, de Pijper C, Verlaan-de Vries M, Bos JL, Leeksma CH, Kerkhofs H et al. Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. Blood 1992; 79: 1266-1270.
46. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542.